Stockreport

Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates

Sana Biotechnology, Inc.  (SANA) 
PDF Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC45 [Read more]